Stock Track | Nurix Therapeutics Soars on Analyst Optimism and Solid Q3 Results

Stock Track10-14

Shares of Nurix Therapeutics (NRIX) surged 5.21% on October 14, 2024, riding on a wave of analyst optimism and better-than-expected quarterly earnings. The biopharmaceutical company's stock closed at $24.30, up $0.67 from the previous trading session.

Analysts from prominent firms such as RBC Capital, Needham, and others maintained their "Buy" or "Outperform" ratings on NRIX, citing promising clinical trials and a strong financial position. Price targets ranged from $15 to as high as $41, reflecting the potential upside analysts see in the company.

NRIX also reported its Q3 2024 financial results, with earnings per share (EPS) of -$0.67 beating analysts' estimates by $0.05. However, revenue for the quarter came in at $12.6 million, missing expectations by $2.04 million. Despite the revenue miss, the company's cash, cash equivalents, and marketable securities stood at a robust $457.5 million as of August 31, 2024, providing ample resources for future growth and development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176536661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-14 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176536661","market":"us","top_or_hot":-1,"title":"Stock Track | Nurix Therapeutics Soars on Analyst Optimism and Solid Q3 Results","media":"Stock Track","content":"<p>Shares of Nurix Therapeutics (NRIX) surged 5.21% on October 14, 2024, riding on a wave of analyst optimism and better-than-expected quarterly earnings. The biopharmaceutical company's stock closed at $24.30, up $0.67 from the previous trading session.</p>\n\n<p>Analysts from prominent firms such as RBC Capital, Needham, and others maintained their \"Buy\" or \"Outperform\" ratings on NRIX, citing promising clinical trials and a strong financial position. Price targets ranged from $15 to as high as $41, reflecting the potential upside analysts see in the company.</p>\n\n<p>NRIX also reported its Q3 2024 financial results, with earnings per share (EPS) of -$0.67 beating analysts' estimates by $0.05. However, revenue for the quarter came in at $12.6 million, missing expectations by $2.04 million. Despite the revenue miss, the company's cash, cash equivalents, and marketable securities stood at a robust $457.5 million as of August 31, 2024, providing ample resources for future growth and development.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Nurix Therapeutics Soars on Analyst Optimism and Solid Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Nurix Therapeutics Soars on Analyst Optimism and Solid Q3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-14 22:16 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Nurix Therapeutics (NRIX) surged 5.21% on October 14, 2024, riding on a wave of analyst optimism and better-than-expected quarterly earnings. The biopharmaceutical company's stock closed at ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRIX","symbol_name":"Nurix Therapeutics","start_time":0,"source_url":"","article_id":"1176536661","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176536661","pubTimestamp":1728915380,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Nurix Therapeutics  surged 5.21% on October 14, 2024, riding on a wave of analyst optimism and better-than-expected quarterly earnings. The biopharmaceutical company's stock closed at $24.30, up $0.67 from the previous trading session.Analysts from prominent firms such as RBC Capital, Needham, and others maintained their \"Buy\" or \"Outperform\" ratings on NRIX, citing promising clinical trials and a strong financial position. Price targets ranged from $15 to as high as $41, reflecting th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRIX":"Nurix Therapeutics"},"translate_title":"Nurix Therapeutics股票因分析师乐观情绪和稳健的第三季度业绩而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRIX":1},"content_text":"Shares of Nurix Therapeutics (NRIX) surged 5.21% on October 14, 2024, riding on a wave of analyst optimism and better-than-expected quarterly earnings. The biopharmaceutical company's stock closed at $24.30, up $0.67 from the previous trading session.\nAnalysts from prominent firms such as RBC Capital, Needham, and others maintained their \"Buy\" or \"Outperform\" ratings on NRIX, citing promising clinical trials and a strong financial position. Price targets ranged from $15 to as high as $41, reflecting the potential upside analysts see in the company.\nNRIX also reported its Q3 2024 financial results, with earnings per share (EPS) of -$0.67 beating analysts' estimates by $0.05. However, revenue for the quarter came in at $12.6 million, missing expectations by $2.04 million. Despite the revenue miss, the company's cash, cash equivalents, and marketable securities stood at a robust $457.5 million as of August 31, 2024, providing ample resources for future growth and development.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176536661"}